ZA201300675B - Methods and compositions for cns delivery of arylsulfatase a - Google Patents

Methods and compositions for cns delivery of arylsulfatase a

Info

Publication number
ZA201300675B
ZA201300675B ZA2013/00675A ZA201300675A ZA201300675B ZA 201300675 B ZA201300675 B ZA 201300675B ZA 2013/00675 A ZA2013/00675 A ZA 2013/00675A ZA 201300675 A ZA201300675 A ZA 201300675A ZA 201300675 B ZA201300675 B ZA 201300675B
Authority
ZA
South Africa
Prior art keywords
arylsulfatase
compositions
methods
cns delivery
cns
Prior art date
Application number
ZA2013/00675A
Other languages
English (en)
Inventor
Pericles Callias
Teresa Leah Wright
Lawrence Charnas
Jing Pan
Zahra Shahrokh
Paul Campolieto
Katherine Taylor
Nazila Salamat-Miier
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of ZA201300675B publication Critical patent/ZA201300675B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2013/00675A 2010-06-25 2013-01-25 Methods and compositions for cns delivery of arylsulfatase a ZA201300675B (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09
PCT/US2011/041926 WO2011163650A2 (fr) 2010-06-25 2011-06-25 Procédés et compositions pour l'administration au snc d'arylsulfatase a

Publications (1)

Publication Number Publication Date
ZA201300675B true ZA201300675B (en) 2017-11-29

Family

ID=46888844

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/00675A ZA201300675B (en) 2010-06-25 2013-01-25 Methods and compositions for cns delivery of arylsulfatase a

Country Status (25)

Country Link
US (1) US9770410B2 (fr)
EP (3) EP3626257B1 (fr)
JP (1) JP6045493B2 (fr)
KR (4) KR102094094B1 (fr)
CN (1) CN103282046B (fr)
AU (4) AU2011270670B2 (fr)
BR (1) BR112012033216B1 (fr)
CA (1) CA2803003C (fr)
CY (2) CY1122282T1 (fr)
DK (1) DK2585104T3 (fr)
ES (1) ES2754776T3 (fr)
HR (1) HRP20191923T1 (fr)
IL (3) IL291556B2 (fr)
LT (1) LT2585104T (fr)
ME (1) ME03647B (fr)
MX (1) MX344795B (fr)
NZ (2) NZ605873A (fr)
PL (2) PL3626257T3 (fr)
RS (1) RS59468B1 (fr)
RU (1) RU2671503C2 (fr)
SI (1) SI2585104T1 (fr)
TW (1) TWI667037B (fr)
UA (1) UA115650C2 (fr)
WO (1) WO2011163650A2 (fr)
ZA (1) ZA201300675B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180130A1 (es) 2010-06-25 2018-01-18 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
US8545837B2 (en) 2010-06-25 2013-10-01 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
UA115650C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс арилсульфатази а
PE20230169A1 (es) 2010-06-25 2023-02-01 Shire Human Genetic Therapies Suministro al sistema nervioso central de agentes terapeuticos
RU2012154576A (ru) 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
WO2013096899A2 (fr) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Formulations stables pour l'administration au système nerveux central d'arylsulfatase a
MX2015008875A (es) * 2013-01-09 2015-10-22 Shire Human Genetic Therapies Metodos para la purificacion de arilsulfatasa a.
BR112015028605A8 (pt) * 2013-05-15 2019-12-24 Univ Minnesota uso de uma composição e uso de um imunossupressor e uma composição
US10208734B2 (en) * 2015-04-23 2019-02-19 Continuum Dynamics, Inc. Lift-driven wind turbine with force canceling blade configuration
ES2866050T3 (es) * 2015-07-10 2021-10-19 Byondis Bv Composiciones que comprenden conjugados de anticuerpos-fármaco duocarmicina
AU2017220100B2 (en) 2016-02-17 2024-04-04 Takeda Pharmaceutical Company Limited Methods and compositions for CNS delivery of arylsulfatase A
HUE057856T2 (hu) * 2016-06-01 2022-06-28 Servier Ip Uk Ltd Polialkilén-oxid-aszparagináz készítményei és eljárás ezek elõállítására és alkalmazására
BR112019013202A2 (pt) * 2016-12-28 2019-12-10 Japan Chem Res formulação liofilizada
AU2018335752A1 (en) 2017-09-22 2020-03-12 Christian HINDERER Gene therapy for treating Mucopolysaccharidosis type ii
AU2018393045A1 (en) 2017-12-19 2020-07-02 Takeda Pharmaceutical Company Limited Purified arylsulfatase A and compositons thereof
WO2020004368A1 (fr) * 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 Formulation liquide aqueuse contenant des protéines
WO2021061517A1 (fr) * 2019-09-23 2021-04-01 University Of Washington Dosage de l'activité enzymatique d'arylsulfatase dans des taches de sang séché par spectrométrie de masse et fluorométrie
WO2024176112A1 (fr) 2023-02-21 2024-08-29 Takeda Pharmaceutical Company Limited Production à grande échelle d'arylsulfatase a recombinante et compositions associées

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743265A (en) 1986-04-23 1988-05-10 Dij Catheter Corp Articulated catheter placement device
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
DK0900569T3 (da) 1997-08-22 2003-01-27 Seikagaku Kogyo Co Ltd Terapeutisk middel til behandling af herniaramt intervertebral diskus
CA2353522A1 (fr) 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Traitement de la maladie de pompe
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US20020099025A1 (en) 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US6866844B2 (en) 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7396811B2 (en) 2001-04-30 2008-07-08 Zystor Therapeutics, Inc. Subcellular targeting of therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
JP2005506340A (ja) 2001-10-16 2005-03-03 シムバイオンティクス インコーポレイテッド 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物
JP5570677B2 (ja) 2002-04-25 2014-08-13 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド α−ガラクトシダーゼＡ欠損症の治療
EP1514106A4 (fr) 2002-05-29 2007-05-09 Zystor Therapeutics Inc Proteines therapeutiques ciblees
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CA2525236C (fr) 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Administration de composes therapeutiques au cerveau et a d'autres tissus
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US8536315B2 (en) * 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
WO2005074888A2 (fr) 2004-02-03 2005-08-18 Biodelivery Sciences International, Inc. Structures cochleaires d'enzymes de remplacement
EP1720405A4 (fr) 2004-02-06 2008-08-27 Biomarin Pharm Inc Fabrication d'enzymes lysosomales hautement phosphorylees et utilisations associees
EP1716232B9 (fr) 2004-02-10 2010-10-13 ZyStor Therapeutics , Inc. Alpha-glucosidase acide et fragments de celle-ci
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JPWO2006121199A1 (ja) 2005-05-11 2008-12-18 日本ケミカルリサーチ株式会社 脂質小胞体組成物
ES2485369T3 (es) * 2005-06-08 2014-08-13 Amicus Therapeutics, Inc. Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
ES2713488T3 (es) * 2006-04-04 2019-05-22 Chiesi Farm Spa Un proceso para la concentración de un polipéptido
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
US8419710B2 (en) 2006-12-06 2013-04-16 Medtronic, Inc. Methods for infusing fluids via an implantable infusion system
US20090041741A1 (en) 2007-03-06 2009-02-12 Saint Louis University Modified enzyme and treatment method
AU2008287340A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
CN101969971A (zh) 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
HUE034850T2 (en) 2008-05-07 2018-03-28 Biomarin Pharm Inc Lysosomal targeting peptides and their use
US8436489B2 (en) 2009-06-29 2013-05-07 Lightsail Energy, Inc. Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange
PE20180130A1 (es) 2010-06-25 2018-01-18 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
RU2012154576A (ru) 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
US8545837B2 (en) 2010-06-25 2013-10-01 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
PE20230169A1 (es) 2010-06-25 2023-02-01 Shire Human Genetic Therapies Suministro al sistema nervioso central de agentes terapeuticos
UA115650C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс арилсульфатази а
EP2588132A4 (fr) 2010-06-25 2014-10-15 Shire Human Genetic Therapies Procédés et compositions pour l'administration au snc de ss-galactocérébrosidase
KR20130043166A (ko) 2010-06-25 2013-04-29 샤이어 휴먼 지네틱 테라피즈 인크. 산필리포 증후군 b형의 치료
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤

Also Published As

Publication number Publication date
BR112012033216A2 (pt) 2020-08-25
KR102094094B1 (ko) 2020-03-27
JP6045493B2 (ja) 2016-12-14
WO2011163650A3 (fr) 2013-06-13
AU2019204051A1 (en) 2019-08-29
EP2585104A4 (fr) 2014-01-15
ME03647B (fr) 2020-07-20
KR20230079472A (ko) 2023-06-07
RS59468B1 (sr) 2019-11-29
CN103282046B (zh) 2015-05-13
IL273854A (en) 2020-05-31
EP2585104A2 (fr) 2013-05-01
WO2011163650A2 (fr) 2011-12-29
MX2013000323A (es) 2013-06-05
CY1124910T1 (el) 2023-01-05
BR112012033216B1 (pt) 2022-10-11
PL3626257T3 (pl) 2022-03-28
KR20210131449A (ko) 2021-11-02
AU2017202289B2 (en) 2019-03-14
IL223758B (en) 2020-04-30
LT2585104T (lt) 2019-10-25
AU2021236557A1 (en) 2021-10-28
EP2585104B1 (fr) 2019-08-21
SI2585104T1 (sl) 2019-11-29
NZ702799A (en) 2016-08-26
KR20200035167A (ko) 2020-04-01
JP2013538788A (ja) 2013-10-17
KR102537084B1 (ko) 2023-05-26
AU2011270670B2 (en) 2017-01-12
IL291556B2 (en) 2024-02-01
CA2803003A1 (fr) 2011-12-29
KR101997935B1 (ko) 2019-10-04
MX344795B (es) 2017-01-05
US20120009171A1 (en) 2012-01-12
US9770410B2 (en) 2017-09-26
UA115650C2 (uk) 2017-12-11
TW201206464A (en) 2012-02-16
ES2754776T3 (es) 2020-04-20
KR20130135821A (ko) 2013-12-11
CY1122282T1 (el) 2020-11-25
IL291556A (en) 2022-05-01
IL273854B (en) 2022-04-01
AU2011270670A1 (en) 2013-02-14
TWI667037B (zh) 2019-08-01
KR102318997B1 (ko) 2021-10-29
EP3964230A1 (fr) 2022-03-09
EP3626257B1 (fr) 2021-08-04
IL291556B1 (en) 2023-10-01
RU2012154574A (ru) 2014-07-27
AU2019204051B2 (en) 2021-07-22
HRP20191923T1 (hr) 2020-01-10
KR20180059580A (ko) 2018-06-04
RU2671503C2 (ru) 2018-11-01
DK2585104T3 (da) 2019-10-14
EP3626257A1 (fr) 2020-03-25
CA2803003C (fr) 2022-11-22
PL2585104T3 (pl) 2020-01-31
AU2017202289A1 (en) 2017-04-27
NZ605873A (en) 2015-02-27
CN103282046A (zh) 2013-09-04

Similar Documents

Publication Publication Date Title
IL291556A (en) Methods and preparations for administration of arylsulfatase a to the central nervous system
HK1214149A1 (zh) 芳基硫酸酯酶 遞送的方法和組合物
IL284599A (en) Methods and preparations for administration of iduronate-2-sulfatase to the central nervous system
EP2588131A4 (fr) Procédés et compositions pour une administration au snc d'héparane n-sulfatase
EP2558120A4 (fr) Procédés et compositions pour administration intranasale
EP2408435A4 (fr) Compositions et procédés pour délivrer un agent à une plaie
EP2624702A4 (fr) Compositions anti-biofilm et procédés d'utilisation
EP2588132A4 (fr) Procédés et compositions pour l'administration au snc de ss-galactocérébrosidase
EP2555788A4 (fr) Procédés et compositions pour la cardioprotection et la régénération cardiaque
EP2793922A4 (fr) Formulations stables pour l'administration au système nerveux central d'arylsulfatase a
EP2558863A4 (fr) Compositions et méthodes pour la caractérisation d'une myopathie
EP2440192A4 (fr) Compositions et procédés pour l'administration de matières
EP2437735A4 (fr) Compositions et procédés pour administrer des substances